The Priority Review

The stream · Daily digest

The stream: Thursday, November 12, 2026

13 briefs from ClinicalTrials.gov, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Clinical trials · 9

  1. Orphalan expands TRADITiONAL study into China, first participant randomised worldwide

    Orphalan SA announced the expansion of its Phase 3 TRADITiONAL Study into China, marking the first participant worldwide randomised at The Second Affiliated Hospital of Zhejiang University School of Medicine. The study evaluates once-daily trientine tetrahydrochloride versus D-penicillamine over 48 weeks.

    Source: Company press release (PR Newswire), November 12, 2026

  2. AbbVie registers Phase 2b/3 study of ABBV-2294 in systemic sclerosis

    The study plans to enroll 580 participants at about 200 sites worldwide, with a planned start date of December 11, 2026. It plans to evaluate the safety and efficacy of the combination of ABBV-722 and upadacitinib versus placebo over 52 weeks with optional extension periods.

    Source: ClinicalTrials.gov registry record, November 12, 2026

  3. Pfizer registers Phase 3 trial of berobenatide in women with stress urinary incontinence and obesity

    The study, titled VESPER-SUI, plans to enroll 900 participants and has a planned start date of November 17, 2026. It aims to learn about the safety and effectiveness of berobenatide in adult women with stress urinary incontinence and obesity or overweight.

    Source: ClinicalTrials.gov registry record, November 12, 2026

  4. Telix registers Phase 3 study of [18F]FET PET in brain metastases

    The study, led by Telix Pharmaceuticals (Innovations) Pty Limited, plans to enroll 381 participants and begin in December 2026. It will evaluate whether [18F]Floretyrosine PET can differentiate tumor progression from treatment-related changes in patients with brain metastases and equivocal MRI findings.

    Source: ClinicalTrials.gov registry record, November 12, 2026

  5. Qilu Pharmaceutical registers Phase 3 trial of QLS4131 in relapsed or refractory multiple myeloma

    The study, first posted on ClinicalTrials.gov on November 12, 2026, plans to enroll 300 participants and has a planned start date of December 30, 2026. It compares QLS4131 injection with the investigator's choice regimen in participants with relapsed or refractory multiple myeloma.

    Source: ClinicalTrials.gov registry record, November 12, 2026

  6. AstraZeneca registers Phase III trial of FDC laroprovstat/rosuvastatin in hypercholesterolemia

    The study plans to enroll 204 participants and is expected to start on December 21, 2026. It aims to evaluate the effect on LDL-C and the safety and tolerability of the fixed-dose combination in lipid-lowering treatment-naïve patients.

    Source: ClinicalTrials.gov registry record, November 12, 2026

  7. Rhythm posts results of Phase 3 setmelanotide trial in genetic obesity

    The study enrolled 296 participants and completed primary data collection on December 19, 2025. Results were first posted on ClinicalTrials.gov on November 12, 2026.

    Source: ClinicalTrials.gov results record, November 12, 2026

  8. Hoffmann-La Roche posts results of Phase III obinutuzumab study in systemic lupus erythematosus

    Results for the study were first posted on ClinicalTrials.gov on November 12, 2026. The Phase III trial enrolled 303 participants, with primary completion on September 15, 2025, and compared obinutuzumab to placebo in patients with active, autoantibody-positive systemic lupus erythematosus receiving standard-of-care therapy.

    Source: ClinicalTrials.gov results record, November 12, 2026

  9. Pfizer posts results of Phase 3 gene therapy study in Duchenne Muscular Dystrophy

    The study, a Phase 3 long-term safety and efficacy follow-up of fordadistrogene movaparvovec, enrolled 7 participants and was terminated. It began on March 13, 2023, with primary completion on September 24, 2025.

    Source: ClinicalTrials.gov results record, November 12, 2026

Policy · 4

  1. Amyris to acquire sweet protein innovator Oobli

    Amyris, Inc. announced it will acquire Oobli, a leading sweet protein innovator, to add a proven protein technology platform to its biomanufacturing capabilities. The acquisition is expected to close in the coming weeks, with all existing customer commitments and brand partnerships honored uninterrupted.

    Source: Company press release (PR Newswire), November 12, 2026

  2. PAI pharma acquires nexus pharmaceuticals expanding sterile injectable portfolio

    PAI pharma announced the acquisition of nexus pharmaceuticals, adding an established commercial portfolio of over 20 hospital injectable products. The deal builds on PAI's investment in domestic sterile manufacturing and expands its hospital-focused pharmaceutical portfolio.

    Source: Company press release (PR Newswire), November 12, 2026

  3. Olympus announces CMS valuation and reimbursement rates for new ESD CPT codes

    Olympus said the U.S. Centers for Medicare & Medicaid Services published final valuations and CY2027 Medicare reimbursement rates for two new Category I CPT codes, CPT 43498 for upper gastrointestinal ESD and CPT 45991 for lower gastrointestinal ESD, effective Jan. 1, 2027. The company noted the rates reflect the clinical complexity and physician work involved in ESD.

    Source: Company press release (PR Newswire), November 12, 2026

  4. Cold Spring Harbor Laboratory hosts 21st Double Helix Medals dinner

    The 21st annual Double Helix Medals dinner raised $6.5 million for CSHL's biological research and education programs. The event honored Dr. Kevin J. Tracey and philanthropist Michael Milken.

    Source: Company press release (PR Newswire), November 12, 2026